Genetics, genomics, targeted therapy, and “personalized” cancer care

If you are still under the illusion that, simply by identifying the precise structure of the deoxyribonucleic acid (DNA) of patients’ cancer cells, we will be able to develop and target drugs that can eliminate specific cancers (or indeed other disorders) in specific individuals, an article by Sharon Begley on the Reuters.com web site should help to disabuse you. … READ MORE …

CE-TRUS-targeted vs. systematic, TRUS-guided biopsy of the prostate to diagnose prostate cancer

Contrast-enhanced, transrectal ultrasound (CE-TRUS) technology has been found to better detect high-grade prostate cancer than conventional forms of TRUS, which may make it a more appropriate method for the diagnosis of clinically important cancers and monitoring low-risk ones with less biopsies. … READ MORE …

Do SPOP mutations define a new molecular subtype of prostate cancer?

A Letter to the Editor just published in the journal Nature Genetics has suggested that that so-called SPOP mutations may be responsible for between 6 and 15 percent of the prostate cancers diagnosed in the USA each year. … READ MORE …

Lowering risk of infections associated with TRUS-guided prostate biopsy: a new standard of care?

A study just published in the April issue of the Journal of Urology appears to show clearly that “targeted” antimicrobial prophylaxis can significantly reduce the risk of infections associated with transrectal ultrasound (TRUS)-guided biopies for risk of prostate cancer. … READ MORE …

If AEZS-108 works in endometrial cancer … will it work in prostate cancer too?

Earlier this week the Canadian biotech company Aeterna Zentaris announced results from a Phase II trial of its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. This may have implications for the potential of AEZS-108 in prostate cancer too. … READ MORE …

Prostate cancer news reports: Wednesday, June 24, 2009

Today’s news reports include discussion of items on:

  • Prostate cancer risk awareness
  • Improving cryotherapy technique with 3D ultrasound
  • Interposition (“sural”) nerve grafting
  • Post-brachytherapy “PSA bounce”
  • The potential of targeted, peptide-linked, α-emitting radioisotopes … READ MORE …

The news report: Friday, April 24, 2009

In today’s news report we touch on papers that address:

  • Genome studies and identification of real genomic risk for prostate cancer
  • More on the potential of 5-ARIs in prevention of prostate cancer
  • Whether we really need more studies on selenium as a potential prostate cancer prevention agent
  • The evolving potential of targeted focal therapy … READ MORE …

All the early Tuesday news: January 6, 2009

There are multiple news reports available today, including coverage of the following:

  • Vegetable consumption and prostate cancer risk
  • Anti-hypertensive medications and prostate cancer risk
  • Prostate cancer incidence among South Indian and Pakistani immigrants to the United States
  • Bladder neck contracture and type of surgery
  • Cytotoxic and targeted chemotherapies in the managment of prostate cancer
  • The impact of race on prostate cancer detection and choice of treatment … READ MORE …

The day’s news update: Thursday, August 14

Today’s prostate cancer news update includes information related to the following areas:

  • Long-term survival of patients with PSA levels ≥ 50 ng/mL who have been treated with radical prostatectomy
  • The current role of bone imaging in the managment of prostate cancer
  • The potential of targeted therapy for androgen-independent prostate cancer, based on expression of specific molecular markers … READ MORE …